Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cozaar for Secondary Prevention of Atrial Fibrillation
NCT01233635Phase 4
Key facts
- Status
- Terminated
- Start
- Nov 2005
- Primary completion
- Nov 2007
- Countries
- 1
- Sponsor
- University of Pittsburgh
- Modality
- Small Molecules
- Drugs
- losartan
- Conditions
- Atrial fibrillation (AFib)
01
Overview
Phase 4, randomised, open-label trial of losartan in Atrial fibrillation (AFib) (3 arms), sponsored by University of Pittsburgh. Primary endpoint: Atrial Fibrillation burden at 1 year. Started Nov 2005; status: terminated.
02
Design
3 arms- Study design
- RandomizedOpen-label
No Drug
Patients not on ACE/ARB randomized to no drug
Start Cozaar
Patients not on ACE/ARB randomized to start Cozaar
Continue Cozaar
Patients on ACE/ARB switched to/continue Cozaar
03
Endpoints
Primary
Atrial Fibrillation burden
Beyond the preview
Go deeper on NCT01233635.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01233635.